Once again, Kidney News brings together two outstanding clinicians, scientists, teachers, and leaders in nephrology and medicine in a “Distinguished Conversation.” Each has transformed the practice of nephrology with excellent examples of bed-to-bench problem-solving, bringing innovative care back to their own as well as to our patients.

Recertification is a significant and evolving issue for practicing nephrologists. In response to physician complaints, the American Board of Internal Medicine (ABIM) has proposed a number of recent modifications to its Maintenance of Certification (MOC) program.

Wildly waving a stack of paper records, budding nephrologist L.O. Henle and medical student Ms. Curious Tubule run down the hall toward Detective Nephron’s office.

Henle (with a smile): A case, a case!

The detective sits facing the window. He is silent for a moment, then quickly turns around.

We are all aware that the landscape for the practice of medicine in the United States is rapidly changing. For Nephrology in particular, how we practice currently will be very different from practice patterns 20, 10, or even 5 years from now. Three recent developments may have significant effects upon the practice of Nephrology:

Bill Bennett, MD, FASN


William Couser, MD

The recent finding that the experimental drug CMX-2043—developed to prevent ischemic-reperfusion injury (IRI)—does not reduce the risk of contrast-induced kidney injury compared to placebo dealt a setback to the search for agents to prevent the condition. The negative clinical trial results were presented at the American College of Cardiology (ACC) meeting, held this spring in Chicago.